{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:38:08Z","timestamp":1791315488283,"version":"4.3.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01579-8","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:23:23Z","timestamp":1788236603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"1579_CR1","first-page":"233","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233\u201354.","journal-title":"CA Cancer J Clin"},{"key":"1579_CR2","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386\u2013422.","journal-title":"Ann Oncol"},{"key":"1579_CR3","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.prp.2009.07.010","volume":"205","author":"J Neumann","year":"2009","unstructured":"Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205:858\u201362.","journal-title":"Pathol Res Pract"},{"key":"1579_CR4","doi-asserted-by":"publisher","unstructured":"Pellatt AJ, Mullany SA, Halabi S et al. KRAS mutation frequency and distribution in colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2024;33(1):38\u201348. https:\/\/doi.org\/10.1158\/1055-9965.EPI-23-0846.","DOI":"10.1158\/1055-9965.EPI-23-0846"},{"key":"1579_CR5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129:1287\u201392.","journal-title":"J Cell Sci"},{"key":"1579_CR6","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer. June 21, 2024. Accessed June 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer"},{"key":"1579_CR7","unstructured":"U.S. Food and Drug Administration. FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer. January 16, 2025. Accessed June 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sotorasib-panitumumab-kras-g12c-mutated-colorectal-cancer"},{"key":"1579_CR8","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","volume":"63","author":"JB Fell","year":"2020","unstructured":"Fell JB, Fischer JP, Baer BR, et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. J Med Chem. 2020;63:6679\u201393.","journal-title":"J Med Chem"},{"key":"1579_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 2020;10:1129\u201339.","journal-title":"Cancer Discov"},{"key":"1579_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","volume":"12","author":"MH Hofmann","year":"2022","unstructured":"Hofmann MH, Gerlach D, Misale S, Petronczki M, Kraut N. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022;12:924\u201337.","journal-title":"Cancer Discov"},{"key":"1579_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Calinisan A, Hartley JK, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10:54\u201371.","journal-title":"Cancer Discov"},{"key":"1579_CR12","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80:2969\u201374.","journal-title":"Cancer Res"},{"key":"1579_CR13","doi-asserted-by":"publisher","first-page":"8895","DOI":"10.1073\/pnas.1404639111","volume":"111","author":"JC Hunter","year":"2014","unstructured":"Hunter JC, Gurbani D, Ficarro SB, et al. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site-directed KRASG12C inhibitor. Proc Natl Acad Sci USA. 2014;111:8895\u2013900.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1579_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli MP, Janes MR, Li LS, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6:316\u201329.","journal-title":"Cancer Discov"},{"key":"1579_CR15","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757\u201365.","journal-title":"N Engl J Med"},{"key":"1579_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388:44\u201354.","journal-title":"N Engl J Med"},{"key":"1579_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1203296","volume":"13","author":"T Sagawa","year":"2023","unstructured":"Sagawa T, Sato Y, Hirakawa M, et al. Case report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer. Front Oncol. 2023;13:1203296.","journal-title":"Front Oncol"},{"key":"1579_CR18","doi-asserted-by":"publisher","unstructured":"Desai J, Garralda E, Kuo J et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024;30:271\u2013278. https:\/\/doi.org\/10.1038\/s41591-023-02696-8.","DOI":"10.1038\/s41591-023-02696-8"},{"key":"1579_CR19","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRASG12C inhibition in cancer. N Engl J Med. 2021;384:2382\u201393.","journal-title":"N Engl J Med"},{"key":"1579_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532\u20136.","journal-title":"Nature"},{"key":"1579_CR21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher A, LoRusso P, Patel MR, et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023;389:710\u201321.","journal-title":"N Engl J Med"},{"key":"1579_CR22","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem. 2022;65:3123\u201334.","journal-title":"J Med Chem"},{"issue":"10","key":"1579_CR23","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.21873\/anticanres.16629","volume":"43","author":"M Kataoka","year":"2023","unstructured":"Kataoka M, Kitazawa M, Nakamura S, et al. Cetuximab enhances the efficacy of MRTX1133, a novel KRAS G12D inhibitor, in colorectal cancer treatment. Anticancer Res. 2023;43(10):4341\u20138. https:\/\/doi.org\/10.21873\/anticanres.16629.","journal-title":"Anticancer Res"},{"key":"1579_CR24","unstructured":"ClinicalTrials.gov. A study of MRTX1133 in patients with advanced solid tumors with KRAS G12D mutation. ClinicalTrials.gov identifier: NCT05737706. Registered February 10, 2023; first posted February 21, 2023. Accessed. June 2026. https:\/\/clinicaltrials.gov\/study\/NCT05737706"},{"key":"1579_CR25","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28:2171\u201382. https:\/\/doi.org\/10.1038\/s41591-022-02007-7.","journal-title":"Nat Med"},{"key":"1579_CR26","doi-asserted-by":"crossref","unstructured":"Knox JE, Jiang J, Burnett GL et al. RM-036 (RMC-9805), a first-in-class covalent KRAS G12D(ON) tri-complex inhibitor, drives profound antitumor activity in KRASG12D-mutant xenograft models. Cancer Res. 2022;82(Suppl 12):Abstract nr 3596. [AACR 2022].","DOI":"10.1158\/1538-7445.AM2022-3596"},{"issue":"6758","key":"1579_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads0239","volume":"389","author":"C Weller","year":"2025","unstructured":"Weller C, Burnett GL, Jiang L, et al. A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors. Science. 2025;389(6758):eads0239. https:\/\/doi.org\/10.1126\/science.ads0239.","journal-title":"Science"},{"key":"1579_CR28","unstructured":"Revolution Medicines. Revolution Medicines presents initial data from zoldonrasib (RMC-9805) monotherapy phase 1 study in patients with KRAS G12D-mutant solid tumors. April 27. 2025. Accessed June 2026."},{"key":"1579_CR29","unstructured":"Revolution Medicines. Revolution Medicines announces FDA Breakthrough Therapy Designation for zoldonrasib in previously treated KRAS G12D-mutant NSCLC. January 8. 2026. Accessed June 2026."},{"key":"1579_CR30","unstructured":"Paterson D. VS-7375 phase 1\/2a: initial safety and efficacy data in KRAS G12D-mutant solid tumors. ASCO Annual Meeting 2025, Abstract. J Clin Oncol. 2025;43(Suppl)."},{"issue":"Suppl 2","key":"1579_CR31","first-page":"S638","volume":"35","author":"AK Kwan","year":"2024","unstructured":"Kwan AK, Piha-Paul SA, Cleary JM, et al. HRS-4642, a KRAS G12D inhibitor: initial results from a phase 1 study in advanced solid tumors. Ann Oncol. 2024;35(Suppl 2):S638\u20139. [ESMO 2024, Abstract 599O].","journal-title":"Ann Oncol"},{"key":"1579_CR32","unstructured":"Koltun ES, Cregg J, Chang S et al. Preclinical characterization of RMC-5127, a potent and selective RAS(ON) G12V inhibitor. Cancer Res. 2024;84(Suppl 7):Abstract nr 5571. [AACR 2024]."},{"key":"1579_CR33","doi-asserted-by":"publisher","first-page":"118570","DOI":"10.1016\/j.bbamcr.2019.118570","volume":"1867","author":"I Khan","year":"2020","unstructured":"Khan I, Rhett JM, O\u2019Bryan JP. Therapeutic targeting of RAS: new hope for drugging the undruggable. Biochim Biophys Acta Mol Cell Res. 2020;1867:118570.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1579_CR34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14:994\u20131017. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0027.","journal-title":"Cancer Discov"},{"key":"1579_CR35","doi-asserted-by":"crossref","unstructured":"Garrido-Laguna I et al. First pan-RAS inhibitor to show clinical activity in PDAC: RMC-6236. ASCO GI 2025, Abstract 722. J Clin Oncol. 2025;43(Suppl 4).","DOI":"10.1200\/JCO.2025.43.4_suppl.722"},{"key":"1579_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim D, Herdeis L, Rudolph D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619:160\u20136.","journal-title":"Nature"},{"key":"1579_CR37","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s43018-024-00800-6","volume":"5","author":"V Thatikonda","year":"2024","unstructured":"Thatikonda V, et al. Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance. Nat Cancer. 2024;5:1352\u201370.","journal-title":"Nat Cancer"},{"key":"1579_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a phase 1 study. Lancet Oncol. 2022;23:115\u201324.","journal-title":"Lancet Oncol"},{"key":"1579_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp SB, Cheng N, Markosyan N, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 2023;13:298\u2013311.","journal-title":"Cancer Discov"},{"issue":"Suppl 16","key":"1579_CR40","first-page":"3005","volume":"41","author":"LS Rosen","year":"2023","unstructured":"Rosen LS, Brana I, Calles A, et al. A phase Ib study of RMC-4630, a potent SHP2 inhibitor, combined with adagrasib in patients with KRAS-mutant solid tumors. J Clin Oncol. 2023;41(Suppl 16):3005. [ASCO 2023 abstract].","journal-title":"J Clin Oncol"},{"key":"1579_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2159-8290.CD-17-1227","volume":"8","author":"M Hazar-Rethinam","year":"2018","unstructured":"Hazar-Rethinam M, Kleyman M, Han GC, et al. Convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAFV600E colorectal cancer. Cancer Discov. 2018;8:417\u201327.","journal-title":"Cancer Discov"},{"key":"1579_CR42","unstructured":"Fell JB et al. BI 1701963, a SOS1:pan-KRAS inhibitor, in combination with trametinib. ASCO. 2022, Abstract 3007."},{"key":"1579_CR43","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu YC, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375:2255\u201362.","journal-title":"N Engl J Med"},{"key":"1579_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323.","journal-title":"Nature"},{"key":"1579_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76756-1","volume":"10","author":"T Sagawa","year":"2020","unstructured":"Sagawa T, Sato Y, Hirakawa M, et al. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab. Sci Rep. 2020;10:19815.","journal-title":"Sci Rep"},{"key":"1579_CR46","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371\u201381.","journal-title":"N Engl J Med"},{"key":"1579_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3322\/caac.21600","volume":"70","author":"JJH Park","year":"2020","unstructured":"Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70:125\u201337. https:\/\/doi.org\/10.3322\/caac.21600.","journal-title":"CA Cancer J Clin"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01579-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:23:26Z","timestamp":1788236606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01579-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1579"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01579-8","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"21 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable (review article).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"203"}}